A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2014
At a glance
- Drugs Tozasertib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 19 Nov 2007 Status changed from in progress to discontinued.
- 06 Nov 2006 Status change
- 08 Sep 2006 New trial record.